Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208313 | SCV000263964 | likely pathogenic | Arrhythmogenic right ventricular cardiomyopathy | 2015-10-23 | criteria provided, single submitter | clinical testing | |
Laboratory for Molecular Medicine, |
RCV000213286 | SCV000271863 | uncertain significance | not specified | 2016-01-26 | criteria provided, single submitter | clinical testing | Variant classified as Uncertain Significance - Favor Pathogenic. The p.Glu301Gly variant in JUP has been reported in the homozygous state in 1 individual with N axos disease (Tradakis 2014), and has also been identified in 1/66640 European c hromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute .org; dbSNP rs782058451). Computational prediction tools and conservation analys is do not provide strong support for or against an impact to the protein. In sum mary, while there is some suspicion for a pathogenic role, the clinical signific ance of the p.Glu301Gly variant is uncertain. |
Labcorp Genetics |
RCV000798524 | SCV000938144 | likely pathogenic | Naxos disease; Arrhythmogenic right ventricular dysplasia 12 | 2023-09-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 301 of the JUP protein (p.Glu301Gly). This variant is present in population databases (rs782058451, gnomAD 0.004%). This missense change has been observed in individuals with clinical features of autosomal dominant JUP-related conditions and/or Naxos disease (PMID: 24884844, 28098346, 33673806). ClinVar contains an entry for this variant (Variation ID: 222662). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Ce |
RCV000996539 | SCV001151299 | uncertain significance | not provided | 2017-09-01 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000996539 | SCV002023199 | pathogenic | not provided | 2020-12-31 | criteria provided, single submitter | clinical testing |